Search | Clinical Trials Finder

Conditions: Traumatic Brain Injury, Military Operations
Interventions: Oxygen 99.7 %, Oxygen 21 %; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 75 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Rheumatoid Arthritis
Interventions: PDA001, Vehicle Controlled Placebo; Biological · Drug
Lead sponsor: Celularity Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 16
States / cities: Anniston, Alabama • Arcadia, California • Los Angeles, California + 12 more

Conditions: Ligament Tear Knee
Interventions: Oxandrolone, Placebo; Drug
Lead sponsor: George F. Hatch; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypoparathyroidism, Chronic Hypoparathyroidism
Interventions: Encaleret, Placebo; Drug
Lead sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company; Industry
Eligibility: 16 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 4
States / cities: Reno, Nevada • Greenville, North Carolina • Morehead City, North Carolina + 1 more

Conditions: Atopic Dermatitis
Interventions: PF-04965842 200 mg, PF-04965842 100 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: Encinitas, California • Los Angeles, California • Largo, Florida + 5 more

Conditions: Early Alzheimer's Disease
Interventions: CT1812, Placebo; Drug
Lead sponsor: Cognition Therapeutics; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 50
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 41 more

Conditions: Healthy Volunteers
Interventions: ABBV-277, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Post Dural Puncture Headache
Interventions: Caffeine, saline; Drug
Lead sponsor: United States Naval Medical Center, Portsmouth; Federal
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Portsmouth, Virginia

Conditions: Plaque Psoriasis
Interventions: PF-06826647 tablet, PF-06826647 oral suspension, Placebo oral solution/suspension, Placebo tablet; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Hypercholesterolemia
Interventions: Evolocumab, Placebo; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 970 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 59
States / cities: Huntsville, Alabama • Mobile, Alabama • Little Rock, Arkansas + 54 more

Conditions: Obesity
Interventions: S-2367 Placebo, S-2367 800 mg, S-2367 1600 mg, Reduced Calorie Diet; Drug · Other
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 724 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 38
States / cities: Mobile, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 35 more

Conditions: Inflammatory Bowel Diseases, Crohn's Disease
Interventions: Placebo, MORF-057; Drug
Lead sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company); Industry
Eligibility: 18 Years to 85 Years
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 25
States / cities: Lancaster, California • San Diego, California • Colorado Springs, Colorado + 21 more

Conditions: Alzheimer's Disease
Interventions: RO4602522, Placebo, Donepezil, Memantine, Rivastigmine, Galantamine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 42
States / cities: Anaheim, California • Fullerton, California • Lomita, California + 36 more

Conditions: Asthma, Aged
Interventions: Self management intervention, placebo group; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 65 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Healthy, Non-Smoking
Interventions: varenicline, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Asthma
Interventions: fluticasone, Standard Asthma Discharge Instructions; Drug · Other
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 3 Years to 12 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Amblyopia, Amblyopia Unilateral, Amblyopia, Anisometropic, Amblyopia Strabismic
Interventions: Valproate, Placebo, Patch; Drug · Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 8 Years to 17 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Budesonide/formoterol pMDI, Budesonide pMDI, Formoterol Turbuhaler; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 143
States / cities: Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 140 more

Conditions: Acute Hereditary Angio Edema
Interventions: OCTA-C1-INH, Placebo; Drug · Other
Lead sponsor: Octapharma; Industry
Eligibility: 2 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Centennial, Colorado • Farmington Hills, Michigan • Toledo, Ohio

Conditions: Pain
Interventions: Montelukast, Placebo; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 3 Years to 8 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Anemia
Interventions: BAY85-3934, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Stress Disorders, Post-Traumatic
Interventions: Balovaptan, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 15
States / cities: Phoenix, Arizona • Bellflower, California • Panorama City, California + 12 more

Conditions: Rheumatoid Arthritis
Interventions: AZD1163, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 29
States / cities: Glendale, Arizona • Prescott Valley, Arizona • Tucson, Arizona + 25 more

Conditions: Postoperative Pain, Inflammation, Osteoarthritis
Interventions: Dexamethasone 10 mg, Dexamethasone 20 mg, Standard multimodal pain management regimen, Placebo; Drug
Lead sponsor: Thomas L Bradbury; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Tucker, Georgia

Search by objective public record fields.

Hyperbaric Oxygen Treatment for Veterans With Traumatic Brain Injury

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis

Oxandrolone Multiligament Knee

Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants

Caffeine Versus Placebo for Spinal Headaches

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound

Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy

Asthma Self-Management in Older Adults

Evaluation of Varenicline Safety, Tolerability, Pharmacokinetics and Pro-Cognitive Effects in Healthy Elderly Non-Smoking Subjects

Inhaled Steroids at Discharge After Emergency Department Visits for Children With Uncontrolled Asthma

Valproate for the Treatment of Residual Amblyopia

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients

Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

Does Montelukast Decrease Post Adenotonsillectomy Pain in Children

Age and Gender Effects on the Pharmacokinetics of BAY85-3934

Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder (PTSD)

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

Steroids in Total Knee Arthroplasty